DIAGNOSTIC VALUE OF LABORATORY TESTS OF WOMEN IN THE DYNAMICS OF TREATMENT OF PERIODONTAL DISEASES CONCOMITANT WITH BACTERIAL VAGINOSIS

Petrushanko T.O., Krutikova A.D., Krutikova E.I.
Ukrainian Medical Stomatological Academy, Poltava

The lack of clear dental screening strategy for women with bacterial vaginosis (BV) leads to inadequate treatment planning, since atypical triggering factors are not considered, despite the given evidence for the presence of chronic generalized inflammatory and inflammatory-dystrophic periodontal diseases in patients with BV. The analysis of the oral fluid, especially its protective properties, is crucial in the noninvasive diagnostics. In this regard, alpha-amylase and secretory IgA (sIgA) are noteworthy. The aim of the research. The paper was aimed at verification of the diagnostic value of laboratory tests of women in the dynamics of the assessment of the outcomes of the recent treatment of inflammatory and inflammatory-dystrophic periodontal diseases in women of reproductive age with bacterial vaginosis by determining the changes in the kinetic activity of alpha-amylase and sIgA concentration. Material and Methods. 50 women of reproductive age have been examined. The subjects were assigned into groups according to their gynecological status: Group I (control) (n=10) included women with the I and II degree of purity of the vagina Group II (n=10) included carriers of Gardnerella vaginalis without diagnosed bacterial vaginosis; Group IIIA (n=15) included women with verified diagnosis of BV who received conventional treatment; Group IIIB (n=15) included women with BV, who received treatment using our patented treatment regimen that takes into account the presence of specific BV-microflora found in the oral cavity in this group of subjects. In the oral cavity the results of the amino-test of the oral fluid were analyzed and kinetic activity of alpha-amylase and sIgA concentration was determined. The presence of Gardnerella vaginalis and Atopobium vaginae in the oral cavity was determined by the polymerase chain reaction (PCR) method. Results. The sIgA level of women with BV was by 30-45% lower as compared to the value of patients without BV. Concentration of oral sIgA in both groups of women was restored after treatment, but the results of the IIIA and IIIB groups after treatment significantly differed (the result of sIgA in subjects of Group IIIB was by 1.33 times higher than the value of Group IIIA), indicating the higher efficacy of the proposed treatment regimen, which takes into account the presence of etiological agents of BV in the oral cavity. The results of the amino test of oral fluid were positive in patients of Group IIIA before treatment in 73.3%, after treatment only in...
Inflammatory and dystrophic periodontal diseases constitute a problem that requires a comprehensive and interdisciplinary approach both in the diagnosis and treatment, since generalized periodontitis is one of the manifestations of numerous somatic diseases. The relation between pathologies of the cardiovascular, nervous, endocrine, digestive, respiratory and immune systems of the body and periodontal lesions has been validated [9,3] and the algorithms for management of such patients have been developed. The lack of clear dental screening strategy for women with bacterial vaginosis (BV) leads to inadequate treatment planning, since atypical triggering factors are not considered, despite the given evidence of presence of chronic generalized inflammatory and inflammatory-dystrophic periodontal diseases in patients with BV [2,3,13].

Currently, the incidence rate of BV in women aged 18-45 years is accounted for 67%-89% [7,8]. The WHO defines bacterial vaginosis as a polymicrobial dysbiotic noninflammatory disease, when the specific and qualitative vectors of the vaginal microflora are shifted to anaerobic microorganisms. The main etiological agents of BV are Gardnerella vaginalis, an optional anaerobe, found in 82% of women with the abovementioned diagnosis, and Atopobium vaginae, which causes frequent clinical relapses [6,8,12]. Considering the prevalence of the mentioned gynecological diagnosis and detection of inflammatory and inflammatory-dystrophic periodontal diseases in women of reproductive age [13], it is advisable to focus on a more detailed examination of women with bacterial vaginosis and clinical manifestations of the inflammatory-dystrophic process in periodontal tissues.

The analysis of the oral fluid, especially its protective properties, is crucial in the noninvasive diagnostics. In this regard, alpha-amylase and secretory IgA (sIgA) are noteworthy. Alpha-amylase of saliva ensures hydrolysis of carbohydrates at the level of α-1,4-glycosidic bonds, responsible for the destruction of cell walls of various microorganisms (for example, cleavage of alpha-glucans in the cell wall of fungi). The normal value of quantitative kinetic activity of this enzyme in the human oral fluid is 160-320 units. In the presence of inflammatory process in the oral cavity, the kinetic activity of the enzyme increases to 500-620 units [2].

sIgA is the main type of immunoglobulins involved in local immunity of the oral cavity. This component of the oral fluid limits the adhesion of microorganisms to the surface of the epithelium and teeth, resulting in the neutralization of enzymes, toxins, and viruses, or acts synergistically with other antibacterial agents such as lysozyme, lactoferrin of saliva peroxidase. The normal concentration of sIgA in saliva is 115.3-299.7. Reduction of sIgA concentration in saliva is stated in chronic inflammatory diseases of the oral cavity, reinfections and allergic reactions [8,12,13].

The aim of the research. The paper was aimed at verification of the diagnostic value of the assessment of the outcomes of the recent treatment of inflammatory and inflammatory-dystrophic periodontal diseases in women of reproductive age with bacterial vaginosis by determining the changes in the kinetic activity of alpha-amylase and sIgA concentration.

Materials and Methods

50 women of reproductive age without severe general somatic and orthodontic pathologies have been examined. The subjects were assigned into groups according to their gynecological status: Group I (control) (n=10) included women with the I and II degree of purity of the vagina; Group II (n=10) included carriers of Gardnerella vaginalis without diagnosed bacterial vaginosis; Group III-A (n=15) included women with verified diagnosis of BV who received conventional treatment; Group III-B (n=15) included women with BV, who received treatment using our patented treatment regimen that takes into account the presence of specific BV-microflora found in the oral cavity in this group of subjects. The dental diagnosis was made on the basis of the conventional dental clinical, paraclinical, and X-ray examination suggested by N.F. Danilevsky (1994) [1]. Gynecologic diagnosis was made by an obstetrician-gynecologist using the Amsel’s criteria. The results of the amino-test of the oral fluid were analyzed in the oral cavity [10]. Determination of the quantitative activity of alpha-amylase in saliva was carried out by the biochemical kinetic method [5]. Determination of the sIgA concentration in mixed saliva was performed by the ELISA method [5]. In the mixed saliva, the presence of Gardnerella vaginalis and Atopobium vaginae in the oral cavity was determined by the polymerase chain reaction (PCR) method.

All subjects underwent professional oral hygiene and sanitation, closed curettage on indications. The subjects of the Group I and II received periodontal treatment according to conventional regimens, if necessary. Women of Group III-A also received treatment according to conventional regimens: local treatment (oral rinses with “Stomatophyte” mouthwash after morning and evening hygienic procedures; applications with “Metrogy-Denta” (for 7 days)); per os: 250 mg “Metronidazole” every 8 hours for 7 days, 50 mg “Fluconazole” once daily (for 7 days), “Simbiter® acidophilic concentrated” probiotic (for 21 days).

The subjects of the Group III-B underwent treatment according to our patented regimen [11]. Local treatment included mouthwashes with “Stomatophyte” after morning and evening hygienic procedures (for 7 days). “Lizak” lozenges at a dosage of 1 lozenge every 6 hours for 5 days, gingival applications with “Metrogy-Denta” twice a day. Upon completion treatment with “Stomatophyte”, applications with “Simbiter® Omega” were prescribed in the silicone dentoalveolar baths overnight (for 21 days). The conventional treatment involved administration of 150 mg Clindamycin every 6 hours (for 5 days), “Simbiter® acidophilic concentrated” probiotic (for 21 days), calcium-D3-Nicomed at a dosage of 1 tab. during evening meal (for 30 days). Treatment of subjects of the Group III was agreed with a gynecologist, taking into account the sensitivity of the BV etiological agents to antibiotic therapy.
Local gynecological therapy involved “Fluomizin” vaginal suppositories every 24 hours (for 10 days), “Simbiter® gynecological” probiotic vaginally (for 21 days).

The findings were processed by the methods of variational statistics [4].

Results and Discussion

Dental clinical examination of the subjects of the Group I revealed clinically intact periodontium in 40% of women and chronic catarrhal gingivitis was diagnosed in 60%. In Group II, only 30% of women had a clinically intact parodentium and chronic catarrhal gingivitis was registered in 70% of women. Chronic catarrhal gingivitis were diagnosed in 33.3% of the examined subjects of Group III-A; initial chronic generalized periodontitis in 53.3%; chronic generalized periodontitis of the first degree in 13.3%. Chronic catarrhal gingivitis was found in 26.7% of subjects of Group III-B; initial chronic generalized periodontitis in 53.3% and chronic generalized periodontitis of the first degree in 20%. The analysis of findings of the periodontal status has established that chronic inflammatory and inflammatory-dystrophic periodontal diseases were found in all subjects with BV, whereas no marked lesions of periodontal tissues were found in the group of women who are carriers of BV pathogens.

Findings of the study of individual factors of the local oral immunity, namely, alpha-amylase and sIgA in mixed saliva are presented in Table 1.

### Table 1

| Indices                             | I (10)    | II (10)   | III-A (15) | III-B (15) |
|-------------------------------------|-----------|-----------|------------|------------|
| Alpha-amylase activity, units       | 230.8±17.42 | 243.26±16.40 | 452.0±12.9* | 443.6±10.91* |
|                                     | p1>0.05   | p1<0.05   | p2<0.05    | p1<0.05    |
| sIgA content                        | 223.7±22.21 | 180.8±17.42 | 97.4±4.43* | 93.5±4.35*  |
|                                     | p1<0.05   | p2<0.05   | p1<0.05    | p3>0.05    |

Notes: in brackets – number of examined women,
- * - significant difference (p<0.05) in comparison with indices of Group I,
- # - significant difference (p<0.05) in comparison with indices of Group II,
p1 – reliability of indices in comparison between Group I, II, III-A and III-B,
p2 – reliability of indices in comparison with Group II and III-A,
p3 – reliability of indices in comparison with Group III-A and III-B.

The rates of alpha-amylase activity in mixed saliva of subjects of Group I and II were within the reference values and showed no significant difference between the groups. The results of examination of women with BV (Group III-A and III-B before treatment) showed no significant difference between the groups, but were much higher the physiological norm, which confirmed the presence of inflammatory process in the oral cavity. The content of sIgA in the oral fluid in control and comparison groups varied within the reference values. The level of sIgA in all examined subjects of Group III-A and III-B was reduced by 30-45%, compared to a similar value in subjects without BV. The increase in kinetic activity of alpha-amylase and decrease in sIgA concentration in the saliva of subjects with BV confirms the presence of chronic inflammatory processes in the oral cavity of women with a specified gynecological disease.

Amino-test of the oral fluid in women of Group I and II showed negative result in all subjects. Positive values were registered in 86.6% and 93.3% of the subjects of Group III-A and III-B, respectively, before medical treatment. Amino-test of oral fluid promotes identification of BV-associated microflora in the oral cavity. Positive amino-test indicates the decline of individual resistance to BV etiological agents and the inability to inactivate their waste products, including volatile amine izonitryl, detected during the test.

Test on the presence of Gardnerella vaginalis and Atopobium vaginae in the oral cavity (namely, gingival sulcus or gingival, periodontal pockets) and vagina was made to objectify the correlations between vaginal dysbiosis and status of the oral biotope, as well as to confirm the results of the amino-test. The presence of microorganisms in both cavities was determined as a qualitative variable. The results are presented in Table 2 and 3.

### Table 2

| Areas of diagnostics | I (10) | II (10) | III-A (15) | III-B (15) |
|----------------------|--------|---------|------------|------------|
| Oral cavity          | 0      | 0       | 84.6*      | 67.9*      |
|                      | p1>0.05| p1>0.05 | p1<0.05    | p1<0.05    |
|                      |        |         | p2<0.05    | p2<0.05    |
|                      |        |         | p3>0.05    | p3>0.05    |
| Vagina               | 0      | 100     | 92.3       | 96.4*      |
|                      | p1>0.05| p1<0.05 | p1<0.05    | p1<0.05    |
|                      |        |         | p2<0.05    | p2<0.05    |
|                      |        |         | p3>0.05    | p3>0.05    |

Notes: in brackets – number of examined women,
- * - significant difference (p<0.05) in comparison with indices of Group I,
- # - significant difference (p<0.05) in comparison with indices of Group II,
p1 – reliability of indices in comparison between Group I, II and III,
p2 – reliability of indices in comparison with Group II and III,
Pp-1 – reliability of indices in comparison with the results of the oral cavity and vagina.
The inflammatory and inflammatory processes of Group A and Group B before treatment, which confirms the presence of this microorganism in the oral cavity by 3.7% higher the percentage found in vagina. The results of the examined cavities reach 80%, which can be considered as a significant statistical confirmation of the correlation between the inflammatory and inflammatory-dystrophic periodontal tissues diseases and BV, as well as the impact on changes in local immunity. In addition, the comparison of the results of the PCR-diagnostics and the amino-test demonstrates the high diagnostic value of the latter.

After the course of treatment, a repeated clinical and laboratory examination of the women was performed. The comparison was made between groups of patients who were treated with different treatment regimens: conventional (III-A) and adapted to act against Gardnerella vaginalis and Atopobium vaginae (III-B).

One of the criteria for efficacy of treatment is the period of elimination of the inflammatory process in periodontal tissues. Generally, the findings of the research have established the positive nature of changes in clinical indices of the state of oral cavity in all subjects in the dynamics of comprehensive treatment. On day 28, the disappearance of clinical signs of gingival inflammation was diagnosed in 84.6% and 96.4% of the subjects of Group III-A and III-B, respectively. The results of the diagnostics of the state of local immunity are presented in Table 4.

---

### Table 3
The results of PCR on the presence of Atopobium vaginae in the oral and virginal cavities of the examined women, %

| Areas of diagnostics | I (10) | II (10) | III-A (15) | III-B (15) |
|----------------------|--------|---------|------------|------------|
| Oral cavity          | 0      | 0       | 84.6*#     | 78.6*#     |
|                      | p1>0.05| p1<0.05 | p2<0.05    | p3>0.05    |
| Vagina               | 0      | 0       | 76.9*#     | 78.6*#     |
|                      | p1>0.05| p1<0.05 | p2<0.05    | p3>0.05    |

Notes: in brackets – number of examined women.
* - significant difference (p<0.05) in comparison with indices of Group I,
# - significant difference (p<0.05) in comparison with indices of Group II,
p1 – reliability of indices in comparison between Group I, II and III,
p2 – reliability of indices in comparison with Group II and III,
p3 – reliability of indices in comparison with the results of the oral cavity and vagina.

### Table 4
Quantitative kinetic activity of alpha-amylose and concentration of slgA in the oral fluid in women with BV before and after treatment (M±m)

| Indices                  | III-A (15) | III-B (15) |
|--------------------------|------------|------------|
|                          | Before treatment | After treatment | Before treatment | After treatment |
| Alpha-amylose activity, units | 452.0±12.9 | 325.30±15.17* | 443.63±10.91# | 245.95±15.35*# |
|                          | p1<0.05    | p1>0.05    | p2<0.05    | p3>0.05    |
| slgA content             | 97.47±4.43 | 145.87±13.12* | 93.53±4.35# | 194.4±15.17*# |
|                          | p1<0.05    | p1>0.05    | p2<0.05    | p3>0.05    |

Notes: in brackets – number of examined women.
* - significant difference (p<0.05) in comparison with indices of Group III-A before treatment,
# - significant difference (p<0.05) in comparison with indices of Group III-B before treatment,
P1 – reliability of indices in comparison between the results of Group III-A and III-B before and after treatment,
P2 – reliability of indices in comparison between the results of Group III-A after treatment and III-B before and after treatment,
P3 – reliability of indices in comparison of the results of Group III-B before and after treatment.

The analysis of the findings has shown no significant difference between the results of alpha-amylose activity and the content of slgA in the oral fluid in women of both groups before treatment, which confirms the similar conditions at the beginning of treatment. After treatment, in women of the Group III-A the kinetic activity of alpha-amylose decreased by 126.7 units, but exceeded the reference values, which emphasizes the presence of in-
flammatory process in the oral cavity. In subjects of Group III-B the same value decline by 197.68 units and was within the reference values, confirming the elimination of previously existing inflammation. Concentration of sIgA in the oral fluid in both groups of women was restored after treatment, but the values of Group III-A and III-B significantly differed after treatment (the result of sIgA in subjects of Group III-B was by 1.33 times higher than the value of Group III-A), indicating the higher efficacy of the proposed treatment regimen, which takes into account the presence of etiological agents of BV in the oral cavity.

To objectify the outcomes of treatment and the effect of the used drug regimens on *Atopobium vaginae* and *Gardnerella vaginalis* the amino-test of the oral fluid of women who underwent the prescribed therapy was made. In the subjects of Group III-A it was positive before treatment in 73.3%; after treatment the rate was reduced to 53.3%, whereas in the subjects of Group III-B the initial result was 80%, and after treatment the decrease to 20% was recorded, indicating much more effective treatment proposed by us. A decrease in the percentage of positive amino-test indicates an increase in local resistance to etiological agents of bacterial vaginosis.

**Conclusions**

The study of individual factors of local oral immunity, such as alpha-amylase and sIgA content in mixed saliva, in the dynamics of treatment of women with inflammatory and inflammatory-dystrophic periodontal diseases concomitant with bacterial vaginosis showed a significant deviation from the reference values of both indices, namely increase of kinetic activity of alpha-amylase and decrease in sIgA concentration. After combined dental and gynecological treatment of patients the change in the studied indices showed more positive dynamics in women who were treated with the proposed treatment regimen, taking into account the presence of BV pathogens in the oral cavity. The analysis of the findings of the research with regard to the rates of local oral immunity and the results of the amino-test and PCR diagnostics has concluded that the significant reduce in the presence of *Gardnerella vaginalis* and *Atopobium vaginae* in the oral cavity after treatment in women of Group III-B is in concordance with a significant improvement of the local immunity rates. The diagnostic value of the utilized laboratory methods of examination of women for their local resistance is sufficient for mass use as a control of the results of periodontal treatment of patients with inflammatory and inflammatory-dystrophic periodontal diseases concomitant with bacterial vaginosis.

**References**

1. Petrushanko T.O., Shulzenko A.D., Krutikova E.I., Sostoyanie ikaney parodonta u zhenschin s bakterialnym vaginozom. Georg.Med.New 2014;12: 24-28.
2. Galich S.R. Bakterialni vaginoz. Zdorov’e Ukrainy. 2012; 4(8):40-42.
3. Dyagterev E.N. Uroven’ alfa-amilazy slyuny kak pokazatel’ stressa i beremenných. Region.anestez. i lechenie.ostrory boi. 2017;1(11):22-28.
4. Vyha G.V.,Serdyuk O.A., Vygodskaya T.V., Fursova A.V. Sekretnyi immunoglobulin A v kontrole adaptivno-kompensatorykh reaktsii organizma cheloveka. Med. Al-favit. Sovremen. Laboratoria. 2011;4:24-26.
5. Lapin A.A., Vyha G.V., Zelenkov V.N. Neinvazivniy metod opredeleniya antioksidantnogo statusa organizma. SPt. Netradic.prirodi.resursy, tehnologii i produkti. 2011;19:9-20.
6. Schoh S.T., Aksamit L.A., Vyha G.V., Vorob’eva E.I., Tcvetkova A.A. Primenenie nesteroidnyh probio-vospalitel’nyh sredstv dlya lecheniya stomatologicheskikh zabelovaniy. Moskva. Medpress-inform. 2011. 82.
7. Kira E. F. Bakterialni vaginoz. Moskva. MIA. 2012. 472.
8. Kisina V.I., Zabiurova K.I. Urogenital’nym infekcii u zhenschin: klinika, diagnostika, lechenie. Moskva. ООО «Медицинское информационное агенство». 2005. 280.
9. Danilevskiy N.F., Borisenko A.B. Zabelovaniya parodonta., Kiev.: Zdorov’ya. 2000. 464.
10. Petrushanko T.O., Krutikova E.I., Shulzenko A.D. Sposob likuvannya parodontytu z vihol’nym vaginozom.Patent Ukrainy na korysny model № 120483, 19.11.2017. byul. № 23.
11. Gerassimov A.N. Medicinskaya statistika. Uchebnoe posobie. Moskva. ООО «Медицинское информационное агенство», 2007. 480.
12. Petrushanko T.O., Krutikova E.I., Shulzenko A.D. Sposob ekspres-diagnostiki roli bakterii u zabelovaniy na rostlinni lotyshyh aminv u zholok z bakterial’nym vaginozom.Patent Ukrainy na korysny model № 99694, 25.06.2015. byul. № 12.
13. Kaydeshiev I.P., Berkalo L.V., Bobovych O.V., Bobrova N.O. Metody klinichnih ta eksperimental’nyh doslidzhenn. Poltava. Polimened 2003. 320.